塞来昔布联合新辅助化疗治疗乳腺癌可能因COX-2表达和ER状态不同而差异化加重结局:REMAGUS02试验的探索性分析
REMAGUS02试验探索性分析纳入156例HER2阴性乳腺癌患者,评估PTGS2表达与塞来昔布联用新辅助化疗对EFS和OS的影响。中位随访94.5个月,塞来昔布组EFS显著更低(HR 1.7,95%CI 1-2.88,P=.046),PTGS2低表达组EFS更低(HR 3.01,95%CI 1.45-6.24,P=.002),交互作用P=.01。结论认为塞来昔布在新辅助化疗期间对乳腺癌生存有不利影响,PTGS2低表达和/或ER阴性肿瘤更明显。
要点
- 中位随访94.5个月,塞来昔布组EFS显著更低(HR 1.7,95%CI 1-2.88,P=.046)。
- PTGS2低表达组(n=100)中塞来昔布组EFS更低(HR 3.01,95%CI 1.45-6.24,P=.002),交互作用P=.01。
- 作者建议乳腺癌新辅助化疗使用多西他赛期间最好避免使用COX-2抑制剂。
核心结论
- 新辅助化疗期间使用塞来昔布对乳腺癌患者生存有不利影响,PTGS2低表达和/或雌激素受体阴性肿瘤中更明显。
- 作者建议乳腺癌新辅助化疗使用多西他赛期间最好避免使用COX-2抑制剂。
研究设计与样本
- REMAGUS02试验(ISRCTN注册号10059974)的探索性分析,纳入156例HER2阴性乳腺癌患者,均有治疗前PTGS2表达数据。
- 患者接受序贯新辅助化疗(表柔比星联合环磷酰胺后多西他赛,联合或不联合塞来昔布)。
- 在乳腺癌细胞系中进行实验验证;CALGB 30801试验(ClinicalTrials.gov标识符NCT01041781)作为独立验证队列。
主要发现
- 中位随访94.5个月,塞来昔布组EFS显著更低(HR 1.7,95%CI 1-2.88,P=.046)。
- PTGS2表达与塞来昔布使用存在显著交互作用(P交互=.01)。
- PTGS2低表达组(n=100)中,塞来昔布组EFS低于标准治疗组(HR 3.01,95%CI 1.45-6.24,P=.002)。
- 塞来昔布使用是无事件生存、无远处复发生存和总生存的不良独立预测因素。
- 在PTGS2低表达细胞系中,多西他赛联合塞来昔布增强细胞活力,而PTGS2高表达细胞系中无此效应。
临床怎么用
- 作者建议乳腺癌新辅助化疗使用多西他赛期间最好避免使用COX-2抑制剂。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The overexpression of cyclooxygenase 2 (COX-2) gene, also known as prostaglandin-endoperoxide synthase 2 ( PTGS2), occurs in breast cancer, but whether it affects response to anticox drugs remains unclear. We investigated the relationships between PTGS2 expression, celecoxib use during neoadjuvant chemotherapy (NAC), and both event-free survival (EFS) and overall survival (OS). MATERIALS AND METHODS: We analyzed a cohort of 156 patients with human epidermal growth factor receptor 2 -negative breast cancer from the REMAGUS02 (ISRCTN Registry No. 10059974) trial with pretreatment PTGS2 expression data. Patients were treated by sequential NAC (epirubicin plus cyclophosphamide followed by docetaxel with or without celecoxib). Experimental validation was performed on breast cancer cell lines. The Cancer and Leukemia Group B (CALGB) 30801 ( ClinicalTrials.gov identifier: NCT01041781) trial that tested chemotherapy with or without celecoxib in patients with lung cancer served as an independent validation cohort. RESULTS: After 94.5 months of follow-up, EFS was significantly lower in the celecoxib group (hazard ratio [HR], 1.7; 95% CI, 1 to 2.88; P = .046). A significant interaction between PTGS2 expression and celecoxib use was detected ( Pinteraction = .01). In the PTGS2-low group (n = 100), EFS was lower in the celecoxib arm (HR, 3.01; 95% CI, 1.45 to 6.24; P = .002) than in the standard treatment arm. Celecoxib use was an independent predictor of poor EFS, distant relapse-free survival, and OS. Celecoxib in addition to docetaxel enhanced cell viability in PTGS2-low cell lines but not in PTGS2-high cell lines. In CALGB 30801, a trend toward poorer progression-free survival was observed in the patients with low urinary metabolite of prostaglandin E2 who received celecoxib (HR = 1.57; 95% CI, 0.87 to 2.84; P = .13). CONCLUSION: Celecoxib use during chemotherapy adversely affected survival in patients with breast cancer, and the effect was more marked in PTGS2-low and/or estrogen receptor-negative tumors. COX-2 inhibitors should preferably be avoided during docetaxel use in patients with breast cancer who are undergoing NAC.
引用
- Hamy AS, Tury S, Wang X, et al. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. J Clin Oncol. 2019. PMID: 30702971. doi:10.1200/JCO.18.00636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。